# Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study

> **NCT00318539** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 90 (—)

## Conditions studied

- Obsessive Compulsive Disorder

## Interventions

- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT00318539
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 90 (—)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318539, "Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00318539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*